Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.40 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30013370 | 1.00 | CES2 (0.50) | CES2CES1ALDH1A1KDM4EBLM | |
| SCHEMBL29971509 | 0.98 | CES2 (0.52) | CES2CES1ALDH1A1KDM4EBLM | |
| SCHEMBL948047 | 0.98 | CES2 (0.52) | CES2CES1ALDH1A1KDM4EBLM | |
| Bromide SCHEMBL9085016 | 0.95 | CES2 (0.50) | CES2CES1ALDH1A1KDM4EBLM | |
| Hydrochloric Acid SCHEMBL23778651 | 0.82 | TSHR (0.52) | ALDH1A1KDM4EBLMLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28555632 | 0.82 | BLM (0.57) | ALDH1A1KDM4EBLMLMNAIDO1 | |
| Hydrochloric Acid SCHEMBL29008442 | 0.82 | BLM (0.57) | ALDH1A1KDM4EBLMLMNAIDO1 | |
| SCHEMBL6337922 | 0.79 | TSHR (0.54) | CES2CES1ALDH1A1KDM4ELMNA | |
| SCHEMBL10495281 | 0.79 | F2 (0.55) | ALDH1A1KDM4EBLMLMNAIDO1 | |
| Hydrochloric Acid SCHEMBL9238589 | 0.79 | CES2 (0.65) | CES2CES1ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2026-01-01 | — | — | US | claimed |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-05 | — | — | US | claimed |
| CN-117926289-A | Method for electrochemically synthesizing N-sulfoamidine derivatives under mild condition | 湘潭大学 | 2024-04-26 | — | — | CN | claimed |
| CN-116947854-A | Preparation method of imidazo [2,1-a ] isoquinoline compound | 赣南师范大学 | 2023-10-27 | — | — | CN | claimed |
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2021-12-09 | — | — | US | claimed |
| EP-3873890-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | Ahammune Biosciences Private Limited (IN) | 2021-09-08 | — | — | EP | claimed |
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2026-01-01 | — | — | US | disclosed |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| CN-119504571-A | Right-embedded alcohol or fenchyl alcohol ester derivatives of 2-hydroxy nicotinic acid and pharmaceutical application thereof | 苏州缘聚医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-117926289-A | Method for electrochemically synthesizing N-sulfoamidine derivatives under mild condition | 湘潭大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-117209438-A | Preparation method of 1,2,4 triazole-3-ketone compound | 五邑大学 | 2023-12-12 | — | — | CN | disclosed |
| CN-116947854-A | Preparation method of imidazo [2,1-a ] isoquinoline compound | 赣南师范大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-115023427-A | Pyrazolotriazines | 拜耳公司 | 2022-09-06 | — | — | CN | disclosed |
| EP-2539326-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20120053343-A1 | TRIAZINE-BASED COMPOUND AND ULTRAVIOLET ABSORBER | FUJIFILM CORPORATION (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2423202-A1 | Triazine-based compound and ultraviolet absorber | Fujifilm Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
| EP-0036711-B1 | PESTICIDAL HETEROCYCLIC COMPOUNDS, PROCESSES FOR PREPARING THEM, COMPOSITIONS CONTAINING THEM, AND THEIR USE | FBC LIMITED (GB) | 1985-12-04 | — | — | EP | disclosed |
| US-4414221-A | MITICIDES, INSECTICIDES, APHIDICIDES | FBC LIMITED (GB) | 1983-11-08 | — | — | US | disclosed |
| US-4102806-A | DISPERSION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | IDO1, IDO2, NFATC1 | GAA 432/4885HTR3E 4082/4885HTR3B 3675/4885 |
| US-20120053343-A1 | TRIAZINE-BASED COMPOUND AND ULTRAVIOLET ABSORBER | H1-2, H1-0, CHRM1 | GAA 4169/4885HTR3E 87/4885HTR3B 139/4885 |
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | MALT1, ADRM1, CYP11B1 | GAA 2511/4885HTR3E 765/4885HTR3B 1344/4885 |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | IDO1, IDO2, NFATC1 | GAA 450/4885HTR3E 4089/4885HTR3B 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.